---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-029142"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-02-07T23:59:59+00:00"
generated_at: "2026-06-27T10:38:00.114733+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CytomX promotes Amy Peterson to President and COO; salary, equity grants disclosed

## Summary
- Dr. Peterson promoted to President and COO effective Feb 2, 2022; previously EVP & Chief Dev. Officer.
- Annual base salary increased to $550,000; discretionary annual bonus target set at 50% of salary.
- Received option for 200,000 shares at $4.13 strike price and 40,000 restricted stock units.
- Dr. Sean McCarthy continues as Chairman and CEO; Peterson assumes President role formerly held by McCarthy.

## SEC filing metadata
- accession: 0001193125-22-029142
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/d198997d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-029142
- JSON: https://secwatch.observer/filing/0001193125-22-029142.json
- Plain text: https://secwatch.observer/filing/0001193125-22-029142.txt

## Key facts
- Executive change
  Sean McCarthy changed role as Chairman and Chief Executive Officer at CytomX Therapeutics, Inc..
  - Role: Chairman and Chief Executive Officer
  source text: Dr. Sean McCarthy will continue in his positions as Chairman and Chief Executive Officer of the Company, while Dr. Peterson assumes the title of President previously held by Dr. McCarthy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm
- Executive change
  Amy Peterson changed role as President and Chief Operating Officer at CytomX Therapeutics, Inc..
  - Action: promoted
  - Role: President and Chief Operating Officer
  source text: On February 2, 2022, the Board of Directors of CytomX Therapeutics, Inc. (the “Company”) promoted Dr. Amy Peterson to serve as President and Chief Operating Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.